studies

metastatic/adv melanoma (mML), pembrolizumab (2mg/kg) vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.86 [0.67; 1.10] 0.86[0.67; 1.10]KEYNOTE-002 (2 mg/kg), 201510%359NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.57 [0.45; 0.73] 0.57[0.45; 0.73]KEYNOTE-002 (2 mg/kg), 201510%359NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 6.11 [2.77; 13.47] 6.11[2.77; 13.47]KEYNOTE-002 (2 mg/kg), 201510%359NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.56 [0.34; 0.93] 0.56[0.34; 0.93]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.44 [0.25; 0.76] 0.44[0.25; 0.76]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.85 [0.32; 2.25] 0.85[0.32; 2.25]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 1.46 [0.40; 5.25] 1.46[0.40; 5.25]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.10 [0.01; 0.81] 0.10[0.01; 0.81]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48] 0.96[0.06; 15.48]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.06; 15.48] 0.96[0.06; 15.48]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.48 [0.02; 14.37] 0.48[0.02; 14.37]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.16 [0.01; 3.17] 0.16[0.01; 3.17]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.23 [0.05; 1.11] 0.23[0.05; 1.11]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.93[0.06; 57.80]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.07 [0.00; 1.17] 0.07[0.00; 1.17]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.93[0.06; 57.80]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 1.93 [0.17; 21.50] 1.93[0.17; 21.50]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24] 0.12[0.01; 2.24]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.08 [0.00; 1.40] 0.08[0.00; 1.40]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.24 [0.01; 5.32] 0.24[0.01; 5.32]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 1.93 [0.06; 57.80] 1.93[0.06; 57.80]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.12 [0.01; 2.24] 0.12[0.01; 2.24]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Vitiligo TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.96 [0.02; 48.69] 0.96[0.02; 48.69]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-002 (2 mg/kg), 2015 0.24 [0.03; 2.13] 0.24[0.03; 2.13]KEYNOTE-002 (2 mg/kg), 201510%349NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-01 16:29 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 283,284,70,235,285,68,127,128,286,69,129 - treatments: 576

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons